MPM BioImpact’s Zymeworks ZYME Stock Holding History

MPM BioImpact’s Portfolio ZYME Stock Details ZYME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-565,249	Closed	-$14.2M	–	46
2026 Q1	$14.2M	Buy	+565,249	New	+$13.4M	1.09%	34

Other funds holding ZYME

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

MPM BioImpact's ZYME Position: Q2 2026 in Review

MPM BioImpact sold out of Zymeworks (ZYME) in Q2 2026, closing a stake of 565,249 shares — an estimated $14.2M sold.

MPM BioImpact first reported a position in ZYME in Q1 2026 and held it in 1 quarter. The position peaked at $14.2M in Q1 2026. 203 funds tracked by Wall St. Rank hold ZYME as of Q2 2026.

MPM BioImpact reported no remaining Zymeworks position as of Q2 2026 after selling out during the quarter.
MPM BioImpact sold 565,249 Zymeworks shares in Q2 2026, an estimated $14.2M.
MPM BioImpact first reported a position in Zymeworks in Q1 2026 and held it in 1 quarter.
MPM BioImpact's Zymeworks position peaked at $14.2M in Q1 2026.
203 funds tracked by Wall St. Rank held Zymeworks as of Q2 2026.

Based on MPM BioImpact's 13F filing for Q2 2026, filed 14 Aug 2026.